Kalaris Therapeutics Inc(KLRS)Earnings, Financials & Key RatiosKalaris Therapeutics Inc (KLRS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's persistent reliance on external funding and the rapid acceleration of cash burn, which reduced the cash balance to $34.4M in 2026Q1, present a significant risk of future equity dilution.
Kalaris Therapeutics Inc (KLRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Kalaris Therapeutics Inc (KLRS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.46vs $0.52+11.5% | — |
| Q2 2026 | Mar 17, 2026 | $0.44vs $0.56+21.4% | — |
| Q4 2025 | Nov 12, 2025 | $0.64vs $0.66+3.0% | — |
| Q3 2025 | Aug 13, 2025 | $0.61vs $0.51-19.6% | — |
Recent stock market news and headlines for Kalaris Therapeutics Inc (KLRS)
Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotechnology executive and board member will assist Kalaris in achieving its next phase of growth
BERKELEY HEIGHTS, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an upcoming presentation of Phase 1a data at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting.
Key metrics vs top competitors for Kalaris Therapeutics Inc (KLRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.83 | $90.33M | -1.69 | — | — | -45.22% | — | |
| $11.51 | $966.21M | -3.41 | — | — | -128.57% | — | |
| $9.21 | $2.13B | 15.35 | 19.63% | 32.43% | 38.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — |
Kalaris Therapeutics Inc (KLRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when KLRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Kalaris Therapeutics Inc (KLRS) stock FAQ — growth, dividends, profitability & financials explained
Kalaris Therapeutics Inc (KLRS) reported a net loss of $44.1M for fiscal year 2025.
Kalaris Therapeutics Inc (KLRS) has a return on equity (ROE) of -45.2%. Negative ROE indicates the company is unprofitable.
Kalaris Therapeutics Inc (KLRS) had negative free cash flow of $49.1M in fiscal year 2025, likely due to heavy capital investments.
